Trust Point Inc. Has $478,000 Stock Holdings in Repligen Corporation (NASDAQ:RGEN)

Trust Point Inc. cut its position in Repligen Corporation (NASDAQ:RGEN - Free Report) by 35.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,756 shares of the biotechnology company's stock after selling 2,030 shares during the period. Trust Point Inc.'s holdings in Repligen were worth $478,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of RGEN. Price T Rowe Associates Inc. MD increased its holdings in shares of Repligen by 11.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock worth $1,027,165,000 after purchasing an additional 743,815 shares during the period. Vanguard Group Inc. boosted its position in shares of Repligen by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock valued at $734,251,000 after buying an additional 56,723 shares during the last quarter. Champlain Investment Partners LLC grew its holdings in shares of Repligen by 8.6% in the fourth quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company's stock worth $222,176,000 after acquiring an additional 122,595 shares during the period. Alliancebernstein L.P. lifted its stake in shares of Repligen by 23.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company's stock worth $145,508,000 after purchasing an additional 191,439 shares during the period. Finally, Point72 Asset Management L.P. boosted its stake in shares of Repligen by 183.1% during the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock worth $132,227,000 after acquiring an additional 594,189 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have commented on the stock. Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target on the stock in a research note on Tuesday, April 29th. Royal Bank Of Canada dropped their price objective on Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. Canaccord Genuity Group decreased their price target on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research note on Wednesday, April 16th. JPMorgan Chase & Co. dropped their price target on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. Finally, Evercore ISI initiated coverage on shares of Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price for the company. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, Repligen has an average rating of "Moderate Buy" and a consensus price target of $173.25.

Repligen Stock Performance

Shares of RGEN traded up $1.29 during mid-day trading on Friday, hitting $118.83. The stock had a trading volume of 742,121 shares, compared to its average volume of 738,206. The company has a quick ratio of 5.79, a current ratio of 6.79 and a debt-to-equity ratio of 0.27. Repligen Corporation has a fifty-two week low of $102.97 and a fifty-two week high of $182.52. The company's fifty day simple moving average is $128.79 and its two-hundred day simple moving average is $142.14. The company has a market cap of $6.68 billion, a PE ratio of -264.07, a PEG ratio of 3.37 and a beta of 1.10.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.35 by $0.04. The firm had revenue of $169.17 million for the quarter, compared to analysts' expectations of $163.65 million. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. Repligen's quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the company earned $0.28 EPS. On average, equities analysts expect that Repligen Corporation will post 1.72 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.